Newsroom
Advanced Search
  • Dec 3, 2019
    CoSara Saragene™ tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus now available for sale and distribution as in vitro diagnostics

    Salt Lake City, Utah – December 3, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...

  • Nov 13, 2019
    Revenue includes sales of infectious disease, mosquito abatement products and AgBio primer design services

    Salt Lake City, Utah – November 13, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...

  • Nov 8, 2019

    Following recent Company news of expansion into Africa with the sale and installation to one of the largest private molecular diagnostics laboratories in Ghana, Co-Diagnostics, Inc. (Nasdaq:...

  • Oct 29, 2019
    Company completes sale and installation to one of the largest private molecular diagnostics labs in Ghana

    Salt Lake City, Utah – October 29, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...

  • Oct 15, 2019
    Vector Smart™ products being presented at 6 vector control conferences in October to prepare for 2020 mosquito season

    Salt Lake City, Utah – October 15, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic...

Show 5102550100 per page